Apr 29, 2016 - use of pharmacometabolomics in earlyâphase drug devel- opment, and conclude with recommendations for applica- tions in clinical trials.
Citation: Clin Transl Sci (2016) 9, 128–138; C 2016 ASCPT. All rights reserved
doi:10.1111/cts.12396
REVIEW
Pharmacometabolomics in Early-Phase Clinical Development T Burt1,∗ and S Nandal2
INTRODUCTION Pharmacometabolomics is an emerging field that uses the body’s complement of metabolites to identify individuals likely to experience treatment or adverse effects. Nevertheless, review of clinicaltrials.gov reveals that
